Clinical Trial Update: A Study of SYS6020 Injection in Refractory Active Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating SYS6020 Injection in patients with refractory active systemic lupus erythematosus; the study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• SYS6020

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: Refractory Active Systemic Lupus Erythematosus | Phase 1 | Status: NOT_YET_RECRUITING